Old Web
English
Sign In
Acemap
>
authorDetail
>
Xue Han
Xue Han
Bristol-Myers Squibb
Rheumatoid arthritis
Medicine
Abatacept
Clinical trial
Internal medicine
4
Papers
3
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors
2021
Xue Han
Francis Lobo
Michael S. Broder
Eunice Chang
Sarah N. Gibbs
David J. Ridley
Irina Yermilov
Show All
Source
Cite
Save
Citations (0)
Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk/prognostic factors, and treatment landscape.
2021
Clinical and Experimental Rheumatology
Mir Sohail Fazeli
Vadim Khaychuk
Keith Wittstock
Xue Han
Grace Crocket
Margaret Lin
Sarah L. Hill
Leticia Ferri
Show All
Source
Cite
Save
Citations (0)
Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.
2021
Leslie R. Harrold
Joshua Bryson
T Lehman
Joe Zhuo
Sheng Gao
Xue Han
Amy Schrader
Sabrina Rebello
Dimitrios A. Pappas
Tanya Sommers
Joel M. Kremer
Show All
Source
Cite
Save
Citations (2)
A budget impact analysis for making treatment decisions based on anti-cyclic citrullinated peptide (anti-CCP) testing in rheumatoid arthritis
2020
Journal of Medical Economics
Sang Hee Park
Xue Han
Francis Lobo
David Kratochvil
Dipen Patel
Show All
Source
Cite
Save
Citations (1)
1